The My Pediatric and Adult Rare Tumor (MyPART) Network is a group of patients, family members, researchers, advocates, and healthcare providers who are working together to find treatments for childhood, teen, and young adult rare solid tumors. MyPART believes that working together will help accelerate the discovery of treatments for rare cancer.
- Rare cancers represent 27% of all cancers and account for 25% of all cancer deaths. Therefore, research to explore new treatments is extremely important.
- The My Pediatric and Adult Rare Tumor (MyPART) Network, coordinated through the National Cancer Institute (NCI) Center for Cancer Research (CCR), was established to bring together patients, their family members, healthcare providers, patient advocates, and researchers to work together to find treatments for rare cancers affecting children, adolescents, and young adults.
- MyPART runs the Natural History Study of Rare Solid Tumors. This study follows people of all ages with rare solid tumors over the course of their disease to learn about how these tumors develop and to discover treatments. Participants are asked to provide a saliva sample, fill out questionnaires on their medical history and their family’s medical history, and fill out surveys about how living with a rare tumor affects aspects of their life. To learn more about the Natural History Study and how to participate, email NCICCRRareTumorClinic@mail.nih.gov and visit the MyPART website at www.cancer.gov/MyPART.
- MyPART hosts rare tumor clinics at the NIH Clinical Center to bring patients with a specific rare tumor together with advocates and expert healthcare providers so they can learn more about the tumor from each other.
- MyPART holds workshops for researchers and clinicians to help them share their research, focus their studies, and design clinical trials.
- MyPART formally partners with patient advocacy organizations to facilitate the exchange of information between patients, healthcare providers, and researchers.
- Visit www.cancer.gov/MyPART to learn more and follow MyPART on Twitter at @NCI_CCR_PedOnc.
ACPMP is thrilled to be a part of this important initiative to advance the research and awareness of rare tumors, including appendiceal tumors. For more information on ACPMP’s participation in this program, please reach out to us at email@example.com.